Precigen, Inc.
NASDAQ:PGEN
Overview | Financials
Company Name | Precigen, Inc. |
Symbol | PGEN |
Currency | USD |
Price | 1.13 |
Market Cap | 330,941,970 |
Dividend Yield | 0% |
52-week-range | 0.65 - 1.93 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Helen Sabzevari MPH, Ph.D. |
Website | https://www.precigen.com |
An error occurred while fetching data.
About Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD